First SCIg Approved for CIDP
HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP
World Haemophilia Day
CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to t…
Patient Enrolled in CSL112 Clinical Trial
The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medi…
Making Forbes’ Top Global Employers List
Global biotech leader rated at no. 42 for patient focus, innovation and sustainable g…
New National Fractionation Agreement
CSL Behring today announced that it has signed an agreement with the National Blood A…
Expansion of CSL Biotech Facility
CSL today officially opened a new AUD$230 million advanced manufacturing facility at …
Leading Active, Fulfilling Lives
Any patients coping with a rare disease knows first-hand how difficult and frustrating it can be to find the correct diagnosis and proper treatment for their condition. Sometimes it takes years. Yet, when the search is over, many people can – and do – lead active, fulfilling lives. Discover the story of Roberta Smith, one of many patients thriving in the face of von Willebrand Disease.
von Willebrand Disease Patient
Roberta refuses to let von Willebrand Disease get in the way of an active and fulfilling life.